DETAILED ACTION
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Applicant’s amendment, filed 09/10/2026, has been entered.
Claims 1-89, 93, 104 have been canceled.
Claims 90-92, 94-103, 105-119 are pending and currently under examination as they read on a method comprising providing a subject genetically engineered T cells and RNA encoding IL-2 in a particle comprising at least one lipid.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 90-92, 94-103, 105-119 are rejected under 35 U.S.C. 103 as being unpatentable over Xu et al. (Oncotarget 2016 7(50):82354-82368) in view of Sahin et al. (US 2016/0250323 A1, “Sahin’323”), Sahin et al. (WO 2016/180467 “Sahin’467”; cited in IDS) and Zhu et al. (Cancer Cell 2015 27:489-501; reference of record).
Applicant’s arguments have been considered but have not been found convincing. The rejection of record can be found in the previous Office Action, mailed 06/10/2026.
Motivation to combine
Applicant argues that Xu evaluates cytokines individually and provides no reason to combine IL-2 with IL-7 or IL-21. Although Xu’s experiments evaluate individual cytokines, its disclosure expressly extends to combinations. In the final Discussion paragraph on page 82365, Xu recommends investigating cytokine combinations because of their distinct effects on T-cell phenotype, expansion, and function. Thus, the proposed combination is supported by an express research direction in Xu.
Sahin ’323 supplies the RNA-delivery teachings. Paragraph 0127 describes compositions of different RNAs expressing multiple proteins, while paragraphs 0134–0135 identify IL-2, IL-7, and IL-21 as cytokine payloads for promoting T-cell expansion, differentiation, and survival. Paragraph 0138 describes association of RNA with cationic lipid particles.
The reason for combining these teachings is to provide complementary cytokine support: IL-2 supports proliferation, while IL-7 and IL-21 offer effects on differentiation and persistence. Delivering the selected cytokines through RNA applies Sahin ’323’s disclosed delivery approach to Xu’s suggested combination strategy. The expected benefit is improved support for the transferred cells; the rationale does not depend on predicting applicant’s precise numerical results. This explanation addresses why the teachings would have been combined, consistent with KSR International Co. v. Teleflex Inc., 550 U.S. 398, 418 (2007), and MPEP §2143.
Alleged teaching away
Applicant’s reliance on the inferior performance of CAR-T cells previously cultured with IL-2 does not fully account for Xu’s separate experiment administering cytokines after cell infusion. In that experiment, IL-2 supplementation produced better tumor control than CAR-T cells alone, although IL-15 and IL-21 performed better. See page 82362, Figure 7 and accompanying text. Xu therefore distinguishes the consequences of ex vivo cytokine exposure from direct administration in vivo.
The Office acknowledges Xu’s concerns regarding IL-2-associated regulatory T-cell expansion and its preference for other cytokines in certain settings. Those concerns must be weighed together with its favorable findings and recommendation to investigate combinations. They do not establish that the proposed combination would have been considered unsuitable. As explained in In re Gurley, 27 F.3d 551, 553 (Fed. Cir. 1994), comparative inferiority does not necessarily establish teaching away where the reference nevertheless identifies usefulness for the relevant purpose. See MPEP §2145
Asserted unexpected results
The Office acknowledges that Example 2 compares IL-2/IL-7 and IL-2/IL-21 combinations with individual cytokines and reports improved accumulation and delayed contraction of CAR-T cells. These findings are relevant evidence and are not dismissed merely because cytokine support was generally known.
Nevertheless, the demonstrated effects arise from a particular experimental regimen involving CLDN6-directed cells, albumin-fused cytokines, and repeated antigen-RNA stimulation. The independent claims encompass a broader range of cells, further cytokines, cytokine forms, and administration regimens. Claims 90, 101, and 116 also do not require the repeated antigen vaccination used in the examples. The IL-7- and IL-21-dependent claims narrow cytokine identity but retain substantial breadth in these other respects.
Accordingly, the reported improvement under the tested conditions does not, without a reasoned basis for extrapolation, establish an unexpected advantage throughout the claimed scope. See MPEP §716.02(d). Testing every embodiment is unnecessary, but the evidence must reasonably support the breadth for which it is offered. The comparisons therefore warrant consideration without being treated as dispositive of all pending claims.
Extended-PK cytokines
Applicant argues that Zhu’s synergy between Fc/IL-2 and TA99 does not predict synergy between two extended-PK cytokines. Zhu is relied upon for its teaching of prolonged IL-2 exposure through half-life extension, rather than as proof that TA99 and IL-7 or IL-21 are interchangeable. Zhu reports extended-half-life IL-2 constructs and their therapeutic use in combination treatment.
For claims 96 and 107, the proposed modification is to encode an extended-PK IL-2 form to prolong cytokine availability. Applicant’s distinction between TA99 and another cytokine does not directly rebut that half-life-extension rationale.
Taken together, the references provide a prima facie rationale for combining cytokine support with RNA delivery and, where claimed, antigen stimulation. Applicant’s arguments do not negate that rationale merely because no individual reference performs the complete claimed method. The ultimate determination must weigh that showing against the demonstrated benefits and the extent to which those benefits reasonably extend across each claim.
Therefore, the rejection is maintained.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 90-92, 94-103, 105-119 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-18 of U.S. Patent 10,799,534 and claims 1-29 of U.S. Patent 12,186,275 in view of Xu et al. (Oncotarget 2016 7(50):82354-82368), Sahin et al. (US 2016/0250323 A1, “Sahin’323”) and Zhu et al. (Cancer Cell 2015 27:489-501).
The patent claims disclosed a method for stimulating an immune response in a mammal comprising administering CAR-T cells targeting to an antigen and administering an RNA encoding the antigen carried in a liposome comprising DOTMA and DOPE. Although the patent claims did not disclose administering cytokines, it would have been obvious to administering RNA-encoded cytokines as recited in the present claims in view of the teachings by Xu et al., Sahin’323 and Zhu et al. for reasons discussed above (see 103).
Applicant’s argument and Examiner’s response are essentially same as above (see 103).
Therefore, the rejection is maintained.
Claims 90-92, 94-103, 105-119 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 10, 12-13, 26, 35-49 of copending Application No. 17757195 in view of Xu et al. (Oncotarget 2016 7(50):82354-82368), Sahin et al. (US 2016/0250323 A1, “Sahin’323”), Sahin et al. (WO 2016/180467 “Sahin’467”; cited in IDS) and Zhu et al. (Cancer Cell 2015 27:489-501).
Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the co-pending application disclosed a method of treatment of cancer comprising administering a CAR T cell. Although the claims did not disclose administering IL-2 and IL-7, it would have been obvious in view of Xu, Sahin’323, Sahin’467 and Zhu discussed above (see 103). Therefore, the co-pending claims render obvious of the present claims.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Applicant’s argument and Examiner’s response are essentially same as above (see 103).
Therefore, the rejection is maintained.
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHARON X WEN whose telephone number is (571)270-3064. The examiner can normally be reached Mon-Fri 8-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Misook Yu can be reached at 571-272-0839. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SHARON X WEN/Primary Examiner, Art Unit 1641